Metadate Er Oral Tablet, Extended Release 10Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Metadate ER: Oral tablet, extended release (10mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_3266.JPG
Metadate ER 10mg ER Tab
UCB Pharma Inc
Pill Identification: MD 561 
Drug Image file DrugItem_8792.JPG
Metadate ER 10mg ER Tab
UCB Pharma Inc
Pill Identification: MD 561 
Drug Image file DrugItem_5254.JPG
Methylin 10mg ER Tablet
Mallinckrodt Inc Pharmaceuticals Group
Pill Identification: 1423  |  M
Drug Image file DrugItem_14135.JPG
Methylphenidate 10mg ER Tablet
Mallinckrodt Inc Pharmaceuticals Group
Pill Identification: 1423  |  M

In-Depth Information

Metadate ER 10mg Extended-Release Tablet

NDC: 530140593
  • Prescription Required
  • Federally Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Attention-deficit Hyperactivity Disorder (ADHD), Narcolepsy

Storage Information
Store at room temperature (between 59 to 86 degrees F)
Protect from light
Protect from moisture
Metadate ER 10mg Extended-Release Tablet
Drug Image file DrugItem_3266.JPG
UCB Pharma Inc
Pill Identification: MD 561 
Shape: oval
Color: white
Drug Image file DrugItem_8792.JPG
UCB Pharma Inc
Pill Identification: MD 561 
Shape: oval
Color: white

Reported Side Effects for Metadate ER 10mg Extended-Release Tablet

Addiction Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Sore Throat Incidence:
<2.8%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
<2.2%*
Severity: MILD
Onset: DELAYED
Heart Attack Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Breakdown Of Muscle Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Brain Attack Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Lightheadedness Incidence:
<6.7%*
Severity: MILD
Onset: EARLY
Neuroleptic Malignant Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Psychosis Incidence:
0.1%*
Severity: MODERATE
Onset: EARLY
Rapid Heart Rate Incidence:
0.7-4.8%*
Severity: MODERATE
Onset: RAPID
Confusion Incidence:
1.2%*
Severity: MODERATE
Onset: EARLY
Emotional Lability Incidence:
1.4-9.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
1.4%*
Severity: MODERATE
Onset: DELAYED
Blurred Vision Incidence:
>1.7%*
Severity: MODERATE
Onset: EARLY
Vomiting Incidence:
1.7-10.2%*
Severity: MILD
Onset: EARLY
Decreased Sexual Desire Incidence:
1.7%*
Severity: MILD
Onset: DELAYED
Balance Problems Incidence:
1.7-2.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
1.7%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
1.9%*
Severity: MILD
Onset: DELAYED
Distressed Incidence:
2.0-2.2%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
2.0-30.6%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
2.0-8.2%*
Severity: MILD
Onset: DELAYED
Restlessness Incidence:
2.0-3.1%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Fever Incidence:
2.0-2.2%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
2.0-16.6%*
Severity: MILD
Onset: EARLY
Eye Pain Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
>2.0%*
Severity: MILD
Onset: EARLY
Rapid Heart Rate Incidence:
2.0-3.1%*
Severity: MODERATE
Onset: EARLY
Irritability Incidence:
2.0-11.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
2.2%*
Severity: MILD
Onset: EARLY
Headache Incidence:
2.4-22.2%*
Severity: MILD
Onset: EARLY
Weight Loss Incidence:
>2.4%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
2.4-12.8%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
4.8-8.2%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
14.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Metadate ER 10mg Extended-Release Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Alcohol and Metadate ER 10mg Extended-Release Tablet(Methylphenidate Hydrochloride)
Alcohol and Methylphenidate Hydrochloride(Methylphenidate Hydrochloride)
Do not drink alcoholic beverages while taking certain forms of Methylphenidate. Side effects from Methylphenidate may get worse if you drink alcohol.
Moderate Lifestyle Interaction
Caffeine-containing Foods/Beverages and Metadate ER 10mg Extended-Release Tablet(Methylphenidate Hydrochloride)
Caffeine-containing Foods/Beverages and Methylphenidate Hydrochloride(Methylphenidate Hydrochloride)
Limit caffeine intake (examples: coffee, teas, colas, chocolate and some herbal supplements) while taking Methylphenidate. Also avoid medicines containing additional Caffeine whenever possible. Side effects from Methylphenidate may get worse if you take excessive Caffeine. Taking a high amount of Caffeine can increase the risk of nausea, nervousness, palpitations, problems with sleep, rapid heartbeat, tremor, or other side effects.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More